Keyword: Novavax

At one point, Novavax’s respiratory syncytial virus shot ResVax was being touted as having the potential to become the top-selling vaccine of all time, but that looks pretty unlikely after another phase 3 flop this year.

This year’s top 15 list has been drawn up to include trials whose failure we judge to have had material consequences on their sponsors and the patients for whom the drugs are being developed. The catalog includes multiple trials for aggressive brain cancer, Alzheimer’s disease, nonalcoholic steatohepatitis and heart disease.